Please use this identifier to cite or link to this item:
|Scopus||Web of Science®||Altmetric|
|Title:||Prognostic significance of early molecular response in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors|
|Citation:||Hematology, 2014; 2014(1):240-243|
|Publisher:||American Society of Hematology|
|David T. Yeung, and Michael J. Mauro|
|Abstract:||A 55-year-old man presented with splenomegaly (10 cm below left costal margin) and leucocytosis (145 × 10(9)/L). Differential showed neutrophilia with increased basophils (2%), eosinophils (1.5%), and left shift including myeloblasts (3%). A diagnosis of chronic myeloid leukemia in chronic phase was established after marrow cytogenetics demonstrated the Philadelphia chromosome. Molecular studies showed a BCR-ABL1 qPCR result of 65% on the International Scale. Imatinib therapy at 400 mg daily was initiated due to patient preference, with achievement of complete hematological response after 4 weeks of therapy. BCR-ABL1 at 1 and 3 months after starting therapy was 37% and 13%, respectively (all reported on International Scale). Is this considered an adequate molecular response?|
|Keywords:||Humans; Protein Kinase Inhibitors; Prognosis; Disease-Free Survival; Treatment Outcome; Middle Aged; Male; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Practice Guidelines as Topic|
|Rights:||© 2015 by the American Society of Hematology|
|Appears in Collections:||Medicine publications|
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.